帕唑帕尼联合吉西他滨对比帕唑帕尼单药治疗蒽环类和/或异环磷酰胺难治性软组织肉瘤:PAPAGEMO 2期随机临床试验最终结果
这项在德国开展的多中心2期随机试验纳入90例蒽环类和/或异环磷酰胺治疗后进展的软组织肉瘤患者,比较帕唑帕尼联合吉西他滨与帕唑帕尼单药的疗效。结果显示联合组12周无进展生存率显著提高(74% vs 47%),中位无进展生存期延长(5.6 vs 2.0个月),但总生存无差异,联合组毒性增加但可控。
要点
- 帕唑帕尼联合吉西他滨较单药显著提高12周无进展生存率(74% vs 47%)。
- 联合组中位无进展生存期延长至5.6个月,单药组为2.0个月。
- 联合方案毒性增加但可管理,主要为血液学毒性,总生存无改善。
核心结论
- 在蒽环类和/或异环磷酰胺难治性软组织肉瘤中,帕唑帕尼联合吉西他滨耐受性可,12周无进展生存率显著高于帕唑帕尼单药。
- 联合方案显示临床活性,但需在更均一的人群(如平滑肌肉瘤)中开展3期试验确认。
研究设计与样本
- 多中心、随机2期临床试验,2011年9月至2014年7月在德国开展。
- 共90例患者随机,86例可评估,中位年龄57岁,ECOG评分0/1者占90%。
- 主要终点为12周无进展生存率,次要终点包括毒性、生活质量、总生存和缓解率。
主要发现
- 联合组毒性增加但可管理,主要为血液学毒性。
临床怎么用
- 对于蒽环类和/或异环磷酰胺难治性软组织肉瘤,可考虑帕唑帕尼联合吉西他滨以提高无进展生存,但需权衡增加的毒性。
- 该联合方案的总生存未获益,临床决策应个体化,并关注血液学毒性管理。
局限性
- 为2期试验,样本量有限,结果需3期试验确认。
- 人群异质性较大,需在更均一人群(如平滑肌肉瘤)中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pazopanib and gemcitabine have shown good tolerability, albeit modest single-agent activity in pretreated soft tissue sarcoma. A combined regimen to improve outcomes is required. OBJECTIVE: To determine the efficacy of gemcitabine and pazopanib compared with pazopanib alone. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized phase 2 clinical trial was conducted in Germany from September 2011 to July 2014 and included patients with an Eastern Cooperative Oncology Group performance status score of 0 to 2, adequate organ function, measurable lesion, and progression after at least 1 prior treatment with anthracyclines and/or ifosfamide. Data analysis was performed during 2019 and 2020. INTERVENTIONS: Patients were randomized to pazopanib with gemcitabine (A) or without gemcitabine (B). MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival rate (PFSR) at 12 weeks; secondary end points included toxicity, quality of life, overall survival, and response rates. RESULTS: A total of 90 patients were randomized, and 86 eligible patients (43 women [50%]) were evaluable, with a median age of 57 (range, 22-84) years and Eastern Cooperative Oncology Group performance status score of 0/1 in 77 participants (90%). The predominant histological subtypes were leiomyosarcoma (22 [26%]) and liposarcoma (16 [19%]). After a median follow-up of 12.4 (range, 1-48) months, the primary end point was met, with a PFSR at 12 weeks of 74% (A) vs 47% (B) (hazard ratio [HR], 1.60; 90% CI, 1.15-2.23; P = .01). In the combination arm, PFSR was significantly longer, with a median of 5.6 vs 2.0 months (HR, 0.58; 95% CI, 0.36-0.92; P = .02) compared with single-agent pazopanib, whereas overall survival was similar, with 13.1 vs 11.2 months (HR, 0.98; 95% CI, 0.60-1.58; P = .83). The objective response rate was overall low, with 11% (A) vs 5% (B) (P = .10). The toxicity of the combination of pazopanib and gemcitabine was increased, but it was manageable and mainly hematological. CONCLUSIONS AND RELEVANCE: This phase 2 randomized clinical trial of patients with soft tissue sarcoma found that the addition of gemcitabine to pazopanib was tolerable, and PFSR at 12 weeks was significantly higher compared with pazopanib alone. These results suggest clinical activity of the combination, but they should be confirmed in a phase 3 trial in a more homogeneous population (eg, leiomyosarcoma). TRIAL REGISTRATION: German Clinical Trials Identifier: DRKS00003139.
引用
- Schmoll HJ, Lindner LH, Reichardt P, et al. Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33355646. doi:10.1001/jamaoncol.2020.6564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。